Healthy adults younger than 65 will no longer be eligible for COVID-19 shots starting in the fall, according to new federal guidelines announced Tuesday.

Schrodinger delivers strong Q1 results, driven by software growth and evolving FDA regulations. Read more to see why SDGR stock is a Buy.

US FDA to change Covid-19 vaccine approval process, limiting access to older adults and those at higher risk. Future shots ...

The FDA also gave full approval to the Novavax COVID vaccine (Nuvaxovid) using this approach, approving it for those ages 65 ...

The Food and Drug Administration is shifting its annual COVID-19 vaccine approval policies to focus on Americans older than ...

Federal officials unveiled a rigorous regulatory approach to future COVID vaccines that could make it harder for many people ...

A new FDA framework for Covid-19 vaccines created confusion among physicians about what it means for young children ...

The new framework unveiled May 20 says new COVID-19 shots should go only to those ages 65 and up or with underlying medical conditions.

Moderna, Inc. (NASDAQ:MRNA) shares soared to the top of the S&P 500 gainers in early afternoon trading on May 20, surging by ...

The US Food and Drug Administration is changing the way it approves Covid-19 vaccines for Americans — a move that will limit ...

Dr. Vinay Prasad, the new director of the FDA's Center for Biologics Evaluation and Research, explained that the changes aim ...

The agency will require manufacturers to conduct randomized, controlled trials to secure approval for healthy Americans.